However, studies on MYCN-amplified NB have identified TP53 as one of the targets of MYCN, with its promoter binding to MYCN and concurrently upregulating several p53 regulatory genes such as MDM2 and PUMA [31], resulting in poor clinical event-free survival and overall survival [32]. The gene discussed is TP53; the disease is neuroblastoma.